Besides, second-generation mTOR inhibitors, which include mTOR and PI3K dual-specificity inhibitors and selective mTORC1/2 inhibitors, are under multiple clinical trials to resolve endocrine resistance of HR+/HER2− BC [33,34]. Here, MTOR is linked to breast cancer.